by Manica Balasegaram, Koert Ritmeijer, Maria Angeles Lima et al.
Expert Opin. Emerging Drugs 2012, 17 (4):493
Liposomal amphotericin B (LAMB), proved to be highly efficacious and safe in over 8000 visceral leishmaniasis (VL) patients treated by Médecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level. Despite requiring higher doses, LAMB is the drug of choice to treat vulnerable groups (e.g., pregnant or HIV positive) and relapsing VL patients in East Africa. LAMB should be included in national VL guidelines and registered in all VL endemic countries. Its cost should be further reduced and regulatory pathways to prove bioequivalence for generic LAMB products should be implemented.